| 吴静芳马志强丁翔赵祥峰杜晓晖.尼莫地平对动脉瘤性蛛网膜下腔出血脑血管痉挛
的临床疗效研究[J].现代生物医学进展英文版,2014,14(17):3319-3321. |
| 尼莫地平对动脉瘤性蛛网膜下腔出血脑血管痉挛
的临床疗效研究 |
| Study on Clinical Effect of Nimodipine on Cerebral Vasospasmafter Aneurysmal Subarachnoid Hemorrhage |
| |
| DOI： |
| 中文关键词: 尼莫地平 蛛网膜下腔出血 脑血管痉挛 临床疗效 |
| 英文关键词: Nimodipine Subarachnoid hemorrhage Cerebral vasospasm Clinical effect |
| 基金项目: |
|
| Hits: 899 |
| Download times: 1014 |
| 中文摘要: |
| 摘要目的：观察尼莫地平对动脉瘤性蛛网膜下腔出血脑血管痉挛的临床疗效及安全性，为临床治疗提供依据。方法：对我院2010
年2 月~2013 年2 月期间收治的92 例动脉瘤性蛛网膜下腔出血患者进行随机分为观察组和对照组，每组46 例。两组患者入院
后均进行常规治疗，绝对卧床休息、镇静、给予氨甲环酸止血、脱水降颅压、防治感染及对症治疗。观察组在上述治疗基础上给予
尼莫地平（德国拜尔公司）持续微泵静脉注射20 mg·d-1，连用14 d，后改为口服尼莫地平片40 mg，qid，至第21 天，根据监测血压
调整剂量。观察两组患者1 个月内脑血管发病情况、CT 评价情况，并进行对比分析。结果：两组患者治疗后，观察组有效率91.3%；
对照组有效率73.91%。两组比较差异明显，观察组疗效明显优于对照组，具有统计学意义（P<0.05）。两组患者在治疗期间，观察组
发生脑血管痉挛4 例，占8.7%；对照组发生脑血管痉挛26 例，占56.52%，两组比较差异明显，具有统计学意义（P<0.05）。结论：尼
莫地平能够显著降低动脉瘤性蛛网膜下腔出血脑血管痉挛的发生率，对脑血管再出血具有积极防治作用，建议推广应用。 |
| 英文摘要: |
| ABSTRACT Objective:To observe the clinical efficacy and safety of nimodipine on cerebral vasospasm after aneurysmal
subarachnoid hemorrhage, and to provide basis for clinical therapy.Methods: 92 cases of patients with aneurysmal subarachnoid
hemorrhage in our hospital fromFebruary 2010 to February 2013 were randomly divided into observation group and control group, each
with 46 cases. Two groups of patients received conventional treatment, absolute bed rest, sedation, given tranexamic acid hemostasis,
lowering the intracranial pressure, prevention of infection and symptomatic treatment. In addition to the above treatment, the observation
group received 20mgod-1 of nimodipine (Bayer company) continued micro-pump infusionfor 14 days, and then oral nimodipine tablets
40 mg, qid, until the 21st day, and the dose was adjusted according to the blood pressure monitored. Mobidity of cerebral vascular and
evaluation of CT were observed and contrastively analyzed. Results:After treatment, effective rates of the observation group and the
control groups were 91.3% and 73.91% respectively, with significant difference. Clinical efficacy of the observation group was
significantly superior that that of the control group, with statistical significance (P<0.05). During the treatment, there were 4 cases (8.7%)
of cerebral angiospasmin the observation group, and 26 cases (56.52%) in the control group, with statistically significant difference (P<0.
05). Conclusion:Nimodipine can significantly reduce the occurrence rate of cerebral vasospasm after aneurysmal subarachnoid
hemorrhage, and has a positive role in the prevention of cerebral vascular hemorrhage, thus is worthy of popularization and application. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
